EFFICACY AND SAFETY OF CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) RESULTS FROM A PHASE II GLOBAL TRIAL

被引：0
|
作者：
Ferreira, Carlos G. [1 ]
Barrios, C. [2 ]
Shaw, Alice T. [3 ]
Shi, Yuankai [4 ]
De Pas, Tommaso M. [5 ]
Yang, Pan C. [6 ]
Riely, Greg J. [7 ]
Crino, Lucio [8 ]
Iyer, Shrividya [9 ]
Polli, Anna [11 ]
Lanzalone, Silvana [11 ]
Kim, Dong W. [10 ]
机构：
[1] Inst Nacl Canc, Div Clin & Translat Res, Rio De Janeiro, Brazil
[2] Pucrs Sch Med, Dept Med, Porto Alegre, RS, Brazil
[3] Massachusetts Gen Hosp, Dept Thorac Oncol, Boston, MA 02114 USA
[4] Chinese Acad Med Sci Cams, Dept Med Oncol, Beijing, Peoples R China
[5] European Inst Oncol, Med Oncol Unit Resp Tract & Sarcomas, Milan, Italy
[6] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[8] S Maria Della Misericordia Hosp, Perugia, Italy
[9] Pfizer, Oncol, New York, NY USA
[10] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[11] Pfizer, Oncol, Milan, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S107 / S108
页数：2
相关论文
共 50 条
  • [1] Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
    Kim, Dong-Wan
    Ahn, Myung-Ju
    Shi, Yuankai
    De Pas, Tommaso Martino
    Yang, Pan-Chyr
    Riely, Gregory J.
    Crino, Lucio
    Evans, Tracey L.
    Liu, Xiaoqing
    Han, Ji-Youn
    Salgia, Ravi
    Moro-Sibilot, Denis
    Ou, Sai-Hong Ignatius
    Gettinger, Scott N.
    Wu, Yi Long
    Lanzalone, Silvana
    Polli, Anna
    Iyer, Shrividya
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Results of A Global Phase II Study with Crizotinib in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
    Riely, G. J.
    Evans, T. L.
    Salgia, R.
    Ou, S. I.
    Gettinger, S. N.
    Otterson, G. A.
    Lanzalone, S.
    Polli, A.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S204 - S204
  • [3] UPDATED RESULTS OF A GLOBAL PHASE II STUDY WITH CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Kim, D.
    Ahn, M.
    Yang, P.
    Liu, X.
    De Pas, T.
    Crino, L.
    Lanzalone, S.
    Polli, A.
    Shaw, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 402 - 402
  • [4] RESULTS OF A GLOBAL PHASE II STUDY WITH CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)
    Kim, D. -W.
    Ahn, M. -J
    Shi, Y.
    De Pas, T. M.
    Yang, P. -C
    Riely, G. J.
    Crino, L.
    Evans, T. L.
    Liu, X.
    Han, J. -Y.
    Salgia, R.
    Lanzalone, S.
    Polli, A.
    Iyer, S.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2012, 23 : 32 - 33
  • [5] Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005
    Crino, L.
    Kim, D.
    Riely, G. J.
    Janne, P. A.
    Blackhall, F. H.
    Camidge, D. R.
    Hirsh, V.
    Mok, T.
    Solomon, B. J.
    Park, K.
    Gadgeel, S. M.
    Martins, R.
    Han, J.
    De Pas, T. M.
    Bottomley, A.
    Polli, A.
    Petersen, J.
    Tassell, V. R.
    Shaw, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA
    Rosado-Buzzo, A.
    Garcia-Mollinedo, L.
    Luna-Casas, G.
    Mould-Quevedo, J. F.
    Gutierrez-Ardila, M., V
    Vargas Zea, N.
    VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
  • [7] EXPLORATORY SUBGROUP ANALYSIS OF CRIZOTINIB EFFICACY AND SAFETY IN ASIAN AND NON-ASIAN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) ENROLLED IN A GLOBAL PHASE II STUDY
    Hida, Toyoaki
    Shi, Yuankai
    Ahn, M-J
    Liu, Xiaoquing
    Shaw, A. T.
    Yang, P-C
    De Pas, T. M.
    Han, J-Y
    Satouchi, M.
    Lanzalone, S.
    Polli, A.
    Kim, Dong-Wan
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S454 - S455
  • [8] ESTIMATING THE BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ARGENTINA
    Wang, B.
    Furnback, W.
    Xuan, J.
    VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [9] CLINICAL EXPERIENCE WITH CRIZOTINIB IN SPECIAL POPULATIONS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Ahn, M-J
    Crino, L.
    Solomon, Ben
    Zhou, Caicun
    Ou, Sai-hong I.
    Selaru, P.
    Cohen, D. P.
    Bartlett, C. H.
    Kim, Dong-wan
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S490 - S491
  • [10] Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Kim, E.
    Usari, T.
    Polli, A.
    Lewis, I.
    Wilner, K.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S134
12345